等待開盤 11-19 09:30:00 美东时间
+0.330
+1.22%
Biogen reports two-year Phase 2 CELIA data showing diranersen slows clinical decline and cuts tau biomarkers in early Alzheimer's disease.
46分钟前
KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX report before the
11-09 04:31
Ionis Pharmaceuticals and Otsuka Pharmaceutical report positive Phase 3 data for ulefnersen, an investigational RNA-targeted drug for ALS.
09-23 00:11
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
09-22 22:40
Ionis Pharmaceuticals shares are trading lower amid sympathy with Novartis afte...
09-05 04:41
Wolfe Research analyst Andy Chen downgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Peer Perform.
07-16 18:40
Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $893.928 million estimate.
07-10 18:14
Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary measures and safety remained favorable.
07-09 20:09
Ionis wins FDA approval for Tryngolza in severe hypertriglyceridemia and signs a Recordati licensing deal for zilganersen
06-26 00:25
GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while launching its final buyback tranche.
05-12 00:03